Versant, AbCellera partner to save steps in creation of mAb start-ups

Now that Versant Ventures has quietly built three start-ups that draw on AbCellera’s expertise, the firm has formalized its relationship with the Canadian antibody discovery company for future companies it intends to create.

Versant’s Jerel Davis told BioCentury that the deal builds upon relationships among individuals at the firm and AbCellera Biologics Inc. (NASDAQ:ABCL) that go back for decades, including a connection between the biotech’s president and CEO, Carl Hansen, and Versant’s Markus Enzelberger...